NCT07088341Not yet recruiting
Role of Programmed Death Ligand 1 in Colorectal Cancer
the Role of Programmed Death Ligand 1 in Diagnosis of Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 28 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. \- Evaluation of diagnostic importance of soluble programmed death ligand-1 in patient with recently diagnosed as Colorectal cancer at different stages of disease . 2. Correlation of SPDL-1 level and clinco-pathological data of patients at presentation .
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 19 Jul 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Assiut University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT07088341
What you commit to
- Study type: Observational
- Planned participants: 90
- From 1 Aug 2025 to the primary completion date, 30 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- 2\. Patients did not undergo colorectal surgery
- \-
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.